II. Pharmacokinetics

  1. Transdermal patch releases hormones at constant rate
    1. Ethinyl Estradiol 20 mcg/day
    2. Norelgestromin 150 mcg/day

III. Technique: 4 week cycles

  1. Patch applied to unbroken skin, and replaced each week for 3 weeks
    1. Upper arm
    2. Buttock
    3. Lower Abdomen
    4. Upper trunk (not on Breasts)
  2. Patch removed for 1 week for withdrawal bleeding
  3. New patch started and replaced each week for 3 weeks

IV. Efficacy

  1. Failure rate: 0.88 pregnancies per 100 woman years
  2. Lower efficacy if weight >198 pounds (90 kg)

V. Adverse effects

  1. Overall patch has similar adverse effects to OCP
  2. Transdermal specific adverse effects
    1. Contact Dermatitis reaction to patch
    2. Detachment rate: 2.8% of patches partially detach
  3. Increased adverse effects in first two months
    1. Vaginal spotting
    2. Breast discomfort (Mastalgia)
  4. Thromboembolism risk may be as high as twice the risk of Oral Contraceptives
    1. Cole (2007) Obstet Gynecol 109(2 Pt 1):339-46 [PubMed]

VI. Benefits

  1. Higher compliance rate than with Oral Contraceptives

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window

Ontology: Contraceptive Patch (C2985284)

Definition (NCI) A dermal patch that contains estrogen and progestin hormones for release and absorption through the skin and into the body to prevent pregnancy.
Definition (NCI_NICHD) A medicated adhesive patch that is placed on the skin to deliver estrogen and progestin hormones for release and absorption through the skin and into the body to prevent pregnancy.
Concepts Medical Device (T074)
LNC LA16581-3
English Contraceptive Patch, Contraceptive patch